ETON Eton Pharmaceuticals Inc

Price (delayed)

$3.55

Market cap

$91.2M

P/E Ratio

88.75

Dividend/share

N/A

EPS

$0.04

Enterprise value

$79.57M

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDIĀ® ...

Highlights
ETON's EPS has surged by 200% since the previous quarter and by 117% year-on-year
The company's net income has surged by 198% QoQ and by 114% YoY
The quick ratio has contracted by 42% YoY and by 10% from the previous quarter
The gross margin has contracted by 2.7% YoY

Key stats

What are the main financial stats of ETON
Market
Shares outstanding
25.69M
Market cap
$91.2M
Enterprise value
$79.57M
Valuations
Price to earnings (P/E)
88.75
Price to book (P/B)
5.89
Price to sales (P/S)
2.59
EV/EBIT
146.8
EV/EBITDA
53.69
EV/Sales
2.25
Earnings
Revenue
$35.3M
EBIT
$542,000
EBITDA
$1.48M
Free cash flow
$5.88M
Per share
EPS
$0.04
Free cash flow per share
$0.23
Book value per share
$0.6
Revenue per share
$1.37
TBVPS
$0.95
Balance sheet
Total assets
$30.79M
Total liabilities
$15.3M
Debt
$5.02M
Equity
$15.49M
Working capital
$8.96M
Liquidity
Debt to equity
0.32
Current ratio
1.59
Quick ratio
1.37
Net debt/EBITDA
-7.85
Margins
EBITDA margin
4.2%
Gross margin
67.2%
Net margin
2.6%
Operating margin
4.4%
Efficiency
Return on assets
2.9%
Return on equity
5.7%
Return on invested capital
N/A
Return on capital employed
3.5%
Return on sales
1.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ETON stock price

How has the Eton Pharmaceuticals stock price performed over time
Intraday
1.14%
1 week
-1.11%
1 month
6.29%
1 year
19.53%
YTD
-18.95%
QTD
7.9%

Financial performance

How have Eton Pharmaceuticals's revenue and profit performed over time
Revenue
$35.3M
Gross profit
$23.72M
Operating income
$1.54M
Net income
$913,000
Gross margin
67.2%
Net margin
2.6%
The company's net income has surged by 198% QoQ and by 114% YoY
The net margin has surged by 190% since the previous quarter and by 111% year-on-year
The operating income has soared by 138% YoY
The company's operating margin has surged by 128% YoY

Growth

What is Eton Pharmaceuticals's growth rate over time

Valuation

What is Eton Pharmaceuticals stock price valuation
P/E
88.75
P/B
5.89
P/S
2.59
EV/EBIT
146.8
EV/EBITDA
53.69
EV/Sales
2.25
ETON's EPS has surged by 200% since the previous quarter and by 117% year-on-year
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 13.8 and 8% less than its last 4 quarters average of 6.3
ETON's equity is up by 38% year-on-year
ETON's P/S is 99% below its 5-year quarterly average of 291.5 and 17% below its last 4 quarters average of 3.1
The revenue is up by 36% YoY and by 8% QoQ

Efficiency

How efficient is Eton Pharmaceuticals business performance
Eton Pharmaceuticals's ROE has soared by 192% from the previous quarter and by 111% YoY
The return on assets has surged by 191% since the previous quarter and by 111% year-on-year
ETON's return on sales has surged by 141% since the previous quarter and by 107% year-on-year

Dividends

What is ETON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ETON.

Financial health

How did Eton Pharmaceuticals financials performed over time
ETON's total assets is 101% more than its total liabilities
The quick ratio has contracted by 42% YoY and by 10% from the previous quarter
Eton Pharmaceuticals's current ratio has decreased by 38% YoY and by 3.6% from the previous quarter
The debt is 68% smaller than the equity
ETON's debt to equity is down by 45% year-on-year and by 9% since the previous quarter
ETON's equity is up by 38% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.